266 related articles for article (PubMed ID: 31400711)
1. Small molecule modulators targeting protein kinase CK1 and CK2.
Qiao Y; Chen T; Yang H; Chen Y; Lin H; Qu W; Feng F; Liu W; Guo Q; Liu Z; Sun H
Eur J Med Chem; 2019 Nov; 181():111581. PubMed ID: 31400711
[TBL] [Abstract][Full Text] [Related]
2. Casein kinases as potential therapeutic targets.
Cozza G; Pinna LA
Expert Opin Ther Targets; 2016; 20(3):319-40. PubMed ID: 26565594
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel CK2 leads by cross-docking based virtual screening.
Sun H; Wu X; Xu X; Jiang Z; Liu Z; You Q
Med Chem; 2014; 10(6):628-39. PubMed ID: 24286395
[TBL] [Abstract][Full Text] [Related]
4. The dark side of protein kinase CK2 inhibition.
Cozza G; Meggio F; Moro S
Curr Med Chem; 2011; 18(19):2867-84. PubMed ID: 21651492
[TBL] [Abstract][Full Text] [Related]
5. Kinase CK2 inhibition: an update.
Cozza G; Pinna LA; Moro S
Curr Med Chem; 2013; 20(5):671-93. PubMed ID: 23210774
[TBL] [Abstract][Full Text] [Related]
6. Casein Kinase II (CK2) as a Therapeutic Target for Hematological Malignancies.
Gowda C; Sachdev M; Muthusami S; Kapadia M; Petrovic-Dovat L; Hartman M; Ding Y; Song C; Payne JL; Tan BH; Dovat S
Curr Pharm Des; 2017; 23(1):95-107. PubMed ID: 27719640
[TBL] [Abstract][Full Text] [Related]
7. Achieving effective and selective CK1 inhibitors through structure modification.
Du C; Yang H; Feng F; Liu W; Chen Y; Sun H
Future Med Chem; 2021 Mar; 13(5):505-528. PubMed ID: 33438471
[TBL] [Abstract][Full Text] [Related]
8. Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer.
Pierre F; Chua PC; O'Brien SE; Siddiqui-Jain A; Bourbon P; Haddach M; Michaux J; Nagasawa J; Schwaebe MK; Stefan E; Vialettes A; Whitten JP; Chen TK; Darjania L; Stansfield R; Bliesath J; Drygin D; Ho C; Omori M; Proffitt C; Streiner N; Rice WG; Ryckman DM; Anderes K
Mol Cell Biochem; 2011 Oct; 356(1-2):37-43. PubMed ID: 21755459
[TBL] [Abstract][Full Text] [Related]
9. Protein kinase CK2 inhibition as a pharmacological strategy.
Borgo C; Ruzzene M
Adv Protein Chem Struct Biol; 2021; 124():23-46. PubMed ID: 33632467
[TBL] [Abstract][Full Text] [Related]
10. Structure-guided discovery of adenosine triphosphate-competitive casein kinase 2 inhibitors.
Patel S; Vyas VK; Sharma M; Ghate M
Future Med Chem; 2023 Jun; 15(11):987-1014. PubMed ID: 37307219
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of protein kinase CK2 by flavonoids and tyrphostins. A structural insight.
Lolli G; Cozza G; Mazzorana M; Tibaldi E; Cesaro L; Donella-Deana A; Meggio F; Venerando A; Franchin C; Sarno S; Battistutta R; Pinna LA
Biochemistry; 2012 Aug; 51(31):6097-107. PubMed ID: 22794353
[TBL] [Abstract][Full Text] [Related]
12. Strategies of Targeting CK2 in Drug Discovery: Challenges, Opportunities, and Emerging Prospects.
Chen Y; Wang Y; Wang J; Zhou Z; Cao S; Zhang J
J Med Chem; 2023 Feb; 66(4):2257-2281. PubMed ID: 36745746
[TBL] [Abstract][Full Text] [Related]
13. Identification and Biological Evaluation of CK2 Allosteric Fragments through Structure-Based Virtual Screening.
Li C; Zhang X; Zhang N; Zhou Y; Sun G; Zhao L; Zhong R
Molecules; 2020 Jan; 25(1):. PubMed ID: 31935979
[TBL] [Abstract][Full Text] [Related]
14. Structure-based identification of novel CK2 inhibitors with a linear 2-propenone scaffold as anti-cancer agents.
Qi X; Zhang N; Zhao L; Hu L; Cortopassi WA; Jacobson MP; Li X; Zhong R
Biochem Biophys Res Commun; 2019 Apr; 512(2):208-212. PubMed ID: 30878184
[TBL] [Abstract][Full Text] [Related]
15. Identification of CK2 inhibitors with new scaffolds by a hybrid virtual screening approach based on Bayesian model; pharmacophore hypothesis and molecular docking.
Di-wu L; Li LL; Wang WJ; Xie HZ; Yang J; Zhang CH; Huang Q; Zhong L; Feng S; Yang SY
J Mol Graph Model; 2012 Jun; 36():42-7. PubMed ID: 22516037
[TBL] [Abstract][Full Text] [Related]
16. Recent Advances in the Discovery of CK2 Allosteric Inhibitors: From Traditional Screening to Structure-Based Design.
Chen X; Li C; Wang D; Chen Y; Zhang N
Molecules; 2020 Feb; 25(4):. PubMed ID: 32079098
[TBL] [Abstract][Full Text] [Related]
17. 2-Phenylamino-6-cyano-1H-benzimidazole-based isoform selective casein kinase 1 gamma (CK1γ) inhibitors.
Hua Z; Huang X; Bregman H; Chakka N; DiMauro EF; Doherty EM; Goldstein J; Gunaydin H; Huang H; Mercede S; Newcomb J; Patel VF; Turci SM; Yan J; Wilson C; Martin MW
Bioorg Med Chem Lett; 2012 Sep; 22(17):5392-5. PubMed ID: 22877629
[TBL] [Abstract][Full Text] [Related]
18. Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2.
Cozza G; Mazzorana M; Papinutto E; Bain J; Elliott M; di Maira G; Gianoncelli A; Pagano MA; Sarno S; Ruzzene M; Battistutta R; Meggio F; Moro S; Zagotto G; Pinna LA
Biochem J; 2009 Jul; 421(3):387-95. PubMed ID: 19432557
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and evaluation of 2-phenylisothiazolidin-3-one-1,1-dioxides as a new class of human protein kinase CK2 inhibitors.
Chekanov MO; Ostrynska OV; Synyugin AR; Bdzhola VG; Yarmoluk SM
J Enzyme Inhib Med Chem; 2014 Jun; 29(3):338-43. PubMed ID: 23578312
[TBL] [Abstract][Full Text] [Related]
20. Structure-based Discovery of Novel CK2α-Binding Cyclic Peptides with Anti-cancer Activity.
Tang S; Zhang N; Zhou Y; Cortopassi WA; Jacobson MP; Zhao LJ; Zhong RG
Mol Inform; 2019 Mar; 38(3):e1800089. PubMed ID: 30307134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
